TY - JOUR T1 - Association of post-traumatic stress disorder, traumatic brain injury, and related synergistic factors with prodromal Parkinson’s Disease: A case-control study of 1.5 million Veterans JF - medRxiv DO - 10.1101/2021.08.21.21262374 SP - 2021.08.21.21262374 AU - Gregory D. Scott AU - Randy Woltjer AU - Joseph F. Quinn AU - Miranda M. Lim Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/23/2021.08.21.21262374.abstract N2 - Objective To measure the association of pre-existing post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI) on subsequent diagnosis of Parkinson’s disease, and to identify common co-occurring sleep, mood, cognitive, and pain disorders that may amplify the association with Parkinson’s disease.Methods Population-based case-control of 1.5 million Veterans within the Veterans Health Administration. Cases of coded Parkinson’s disease were matched 4:1 to controls by gender, birth year, age, race, ethnicity, and smoking. For each disorder, the onset, first increase, and synergy index combined with post-traumatic stress disorder and traumatic brain injury were measured.Results Onset times for post-traumatic stress disorder and traumatic brain injury were -22.5 and -10.1 years before diagnosis of Parkinson’s disease. For post-traumatic stress disorder, synergy was greatest with chronic pain, mild cognitive impairment, Rapid eye movement behavior sleep disorder, and periodic limb movement disorder and started at -11, -9, -6, -7 years. For traumatic brain injury, synergy was greatest with migraine, anxiety, sleep apnea, hypersomnia, insomnia, and depression and started at -8, -8, -12, -6, -4, and -5 years.Interpretation There is a long timeline of association of post-traumatic stress disorder and traumatic brain with prodromal Parkinson’s disease and greater-than-additive interactions with other non-motor neurobehavioral disorders. These data provide a more detailed timecourse for post-traumatic stress disorder and traumatic brain injury and identify early synergies potentially worth targeting in clinical trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding for this work. There are no other third party payments or services to disclose.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Portland VA institutional IRB approval (MIRB #04744)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAbstracted and fully de-identified data can be made available upon request with appropriate approvals. ER -